Novo Nordisk (NVO) Up 3% as Haemophilia Drug Meets Study Goals

Novo Nordisk (NVO) achieved co-primary endpoints in a late-stage study evaluating the efficacy and safety of once-weekly and once-monthly subcutaneous Mim8 compared with no prophylaxis and prior coagulation factor prophylaxis treatment in haemophilia A patients aged 12 years or older with or without inhibitors.Mim8 is NVO’s next-generation FVIIIa mimetic bispecific antibody. Per the data readout, the phase IIIa FRONTIER 2 study demonstrated a statistically significant and superior reduction of treated bleed ...